Tokyo, Oct. 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063214) titled 'Co-occurring genomic alterations and outcomes of ALK inhibitor therapy in ALK-positive non-small cell lung cancer' on Oct. 8.
Study Type:
Observational
Primary Sponsor:
Institute - Saiseikai Matsusaka Municipal Hospital
Condition:
Condition - ALK-rearranged Non-small cell lung cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To describe the distribution of pretreatment co-occurring genomic alterations in ALK-positive non-small cell lung cancer and to exploratorily evaluate the associations of TP53, RB1, and MTAP alterations with progression-free survival...